MedTrace Logo

Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients

NCT04672564 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2023-02-23

No results posted yet for this study

Summary

This is a randomized, multicenter, placebo-controlled, double-blind clinical study in patients hospitalized due to severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.

Conditions

  • Coronavirus Disease 2019

Interventions

DRUG

Carrimycin

Carrimycin (400 mg) will be given once-daily for 14 days (2 x 200 mg tablets) after a meal, if a patient experiences an eating problem, carrimycin will be taken without food.

DRUG

Placebo

Placebo will be given once-daily for 14 days (2 tablets) after a meal, if a patient experiences an eating problem, placebo will be taken without food.

Sponsors & Collaborators

  • Shenyang Tonglian Group CO., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-30
Primary Completion
2022-03-24
Completion
2022-05-09
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Brazil
  • Mexico
  • Philippines
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04672564 on ClinicalTrials.gov